New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
12:25 EDTZMH, JNJ, GMED, COV, WMGI, SNN, SYK, NUVA, ARTCAnother bidder may emerge for ArthroCare, says William Blair
William Blair says it would not be surprised to see another bidder emerge for ArthroCare (ARTC). The firm lists Johnson & Johnson (JNJ) and Stryker (SYK)) as the most likely to submit a competing bid to Smith & Nephew's (SNN), and notes Biomet, Zimmer (ZMH) and Covidien (COV) could also have interest in the company. Should the deal for ArthroCare close as currently contemplated, William Blair thinks peers Globus Medical (GMED), NuVasive (NUVA) and Wright Medical (WMGI) could be takeover targets.
News For ARTC;SNN;GMED;NUVA;WMGI;JNJ;SYK;COV;ZMH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
January 20, 2015
08:18 EDTJNJJohnson & Johnson sees 10 major Pharmaceuticals filings from 2013-2017
Sees 10 major filings, 25 line extensions in Pharmaceuticals expected between 2013-2017. Sees about 100 ongoing discovery projects, 50 novel compounds in early development, 5 breakthrough designations. Sees 30 major Medical Devices filings expected from 2014-2016, 20 key Consumer product launches expected global in 2015. Says near-term priorities include: Accelerating growth in Medical Devices through innovation, expanding market leadership in key consumer segments like OTC, Oral Care, Baby and Beauty. Comments from slides that will be presented on the Q4 earnings conference call.
07:52 EDTJNJJohnson & Johnson reports Q4 Pharmaceutical sales $8B
Subscribe for More Information
07:48 EDTJNJJohnson & Johnson sees FY15 adjusted EPS $6.12-$6.27, consensus $6.13
Subscribe for More Information
07:46 EDTJNJJohnson & Johnson reports Q4 EPS ex-items $1.27, consensus $1.26
Subscribe for More Information
January 16, 2015
16:29 EDTJNJOn The Fly: Closing Wrap
Subscribe for More Information
13:01 EDTJNJEarnings Preview: Johnson & Johnson reports after recent Goldman downgrade
Subscribe for More Information
12:43 EDTJNJOn The Fly: Midday Wrap
Subscribe for More Information
08:58 EDTJNJRoth Capital says Depomed now leading pain company, ups to Buy
Roth Capital upgraded Depomed (DEPO) to Buy from Neutral saying the Nucynta transaction transforms the company into a "leading pain company now with critical mass." Roth raised its price target for shares to $25. Depomed last night announced that it acquired the U.S. rights to the Nucyntafranchise for $1.05B from Johnson & Johnson's (JNJ) Jansen unit. Depomed is trading up 9% in pre-market trading to $19.19.
08:12 EDTJNJJohnson & Johnson forms Ebola vaccine development consortia
Subscribe for More Information
January 15, 2015
16:08 EDTJNJJ&J unit sells U.S. Nucynta license rights to Depomed for $1.05B
Subscribe for More Information
16:08 EDTJNJDepomed to acquire U.S. rights to NUCYNTA franchise for $1.05B from Jansen
Subscribe for More Information
16:05 EDTJNJDepomed to acquire U.S. rights to NUCYNTA franchise for $1.05B from Jansen
12:10 EDTJNJJohnson & Johnson volatility elevated into Q4 and outlook
Johnson & Johnson January weekly call option implied volatility is at 22, February is at 16, April is at 15; compared to its 26-week average of 15 according to Track Data, suggesting large movement into the expected release of Q4 results on January 20.
11:20 EDTJNJGoldman cuts J&J to sell citing competitive pressures
Subscribe for More Information
10:00 EDTJNJOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: American Campus (ACC) downgraded to Sell from Neutral at Goldman... Apple (AAPL) downgraded to Neutral from Buy at Mizuho... Archer Daniels (ADM) downgraded to Neutral from Buy at Goldman... Barrick Gold (ABX) downgraded to Underweight from Equal Weight at Barclays... CNOOC (CEO) downgraded to Underperform from Hold at Jefferies... CSC (CSC) downgraded to Underweight from Neutral at JPMorgan... Computer Programs (CPSI) downgraded to Market Perform from Outperform at William Blair... D.R. Horton (DHI) downgraded to Neutral from Buy at UBS... DDR Corp. (DDR) downgraded to Neutral from Overweight at JPMorgan... Dominion Diamond (DDC) downgraded to Equal Weight from Overweight at Barclays... EVERTEC (EVTC) downgraded to Neutral from Overweight at JPMorgan... Education Realty (EDR) downgraded to Sell from Neutral at Goldman... Franco-Nevada (FNV) downgraded to Underweight from Equal Weight at Barclays... General Cable (BGC) downgraded to Neutral from Buy at Longbow... Green Dot (GDOT) downgraded to Neutral from Overweight at JPMorgan... Greif (GEF) downgraded to Neutral from Buy at BofA/Merrill... Grupo Simec (SIM) downgraded to Neutral from Buy at Goldman... Hecla Mining (HL) downgraded to Hold from Buy at BB&T... Host Hotels (HST) downgraded to Hold from Buy at MLV & Co.... Ingredion (INGR) downgraded to Sell from Neutral at Goldman... Insulet (PODD) downgraded to Market Perform from Outperform at Raymond James... Johnson & Johnson (JNJ) downgraded to Sell from Neutral at Goldman... Magna (MGA) downgraded to Hold from Buy at TD Securities... Molson Coors (TAP) downgraded to Neutral from Buy at Goldman... Nuverra Environmental (NES) downgraded at Roth Capital... Omnicom (OMC) downgraded to Hold from Buy at Evercore ISI... PetroChina (PTR) downgraded to Underperform from Hold at Jefferies... Philip Morris (PM) downgraded to Sell from Neutral at Goldman... Precision Castparts (PCP) downgraded to Hold from Buy at KeyBanc... Rio Tinto (RIO) downgraded to Neutral from Outperform at Macquarie... STAG Industrial (STAG) downgraded to Neutral from Overweight at JPMorgan... Silicon Laboratories (SLAB) downgraded to Equal Weight from Overweight at Barclays... Sinopec (SNP) downgraded to Underperform from Hold at Jefferies... Sky (SKYAY) downgraded to Neutral from Outperform at Exane BNP Paribas... Teledyne (TDY) downgraded to Underweight from Hold at KeyBanc... Woodward (WWD) downgraded to Underweight from Hold at KeyBanc... Xilinx (XLNX) downgraded to Equal Weight from Overweight at Barclays.
07:06 EDTJNJJohnson & Johnson downgraded at Goldman
Subscribe for More Information
06:44 EDTJNJJohnson & Johnson downgraded to Sell from Neutral at Goldman
January 14, 2015
10:10 EDTSYKHigh option volume stocks
Subscribe for More Information
09:51 EDTJNJJohnson & Johnson unit says study shows consistent Xarelto safety
Johnson & Johnson unit Janssen announced that a new post-marketing study evaluating the safety of once-daily Xarelto shows, in patients with non-valvular atrial fibrillation, rates and patterns of major bleeding in routine clinical practice are generally consistent with those observed in Phase 3 clinical trials used to approve the medicine for this indication. The fifteen-month results, published today in Clinical Cardiology, represent initial findings from an ongoing, five-year, observational study of patients using Xarelto daily over the course of their lives.
07:37 EDTNUVAJPMorgan to hold a conference
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use